definiens: shall mean a narrative summary report prepared by [COMPANY] ofunaudited clinical data obtained by [COMPANY] for patients enrolled in the AP23573 Phase 1 Clinical Trials as of the datewhich is three weeks preceding the date of each such summary report . Each such narrative summary report shallsummarize each protocol, the number of enrolled patients receiving each dosage level in accordance with eachprotocol, and the safety information ( which shall comprise all Adverse Events reported on draft data listings and required to be reported to any Regulatory Authority ) obtained by [COMPANY] . For purposes ofclarity, all AP23573 Phase 1 Clinical Data ( i ) is subject to change after audit, ( ii ) shall be treated as ConfidentialInformation of [COMPANY], ( iii ) shall be used by MEDINOL solely for internal purposes in performing its obligations and / orexercising its rights under this Agreement and the Supply Agreement, and ( iv ) shall not be disclosed by MEDINOL toany Third Party under any circumstances without [COMPANY] ’s prior written consent